|
Patent landscape, scope, and claims: |
US Patent 10,240,152 (Transthyretin dsRNA) Scope, Claim Coverage, and US Patent Landscape
The US patent 10,240,152 protects a tightly defined dsRNA (antisense SEQ ID NO:450 “core” and sense complement; 19 to 24 nt; with chemical modifications) that inhibits transthyretin (TTR) using quantitative potency thresholds (cell mRNA knockdown and human serum TTR protein reduction) and defined lipid or LNP delivery compositions. The enforceable scope is concentrated in: (i) the specific antisense motif “AUGGAAUACUCUUGGUUACNN (SEQ ID NO:450)” plus complement; (ii) length and modification constraints; (iii) in vivo pharmacodynamic thresholds tied to dosing; and (iv) specific LNP lipid mixtures (including MC3/DSPC/Chol/PEG2000-C14 at ~50/10/38.5/1.5 mol%).
What claims are protected by US Patent 10,240,152 for dsRNA that inhibits transthyretin (TTR)?
Core protection (composition + performance + delivery): Claim set covers pharmaceutical compositions of dsRNA that inhibit TTR expression, plus methods of using those compositions in cells and in humans with transthyretin amyloidosis.
Independent claim logic (Claims 1–4)
Claim 1 (broadest independent frame):
- dsRNA is sense/antisense strands.
- Antisense strand length: 19–24 nt.
- Antisense sequence includes AUGGAAUACUCUUGGUUACNN (SEQ ID NO:450) with NN trailing ambiguity.
- Sense strand length: 19–24 nt; sequence is complementary to antisense.
- dsRNA includes at least one chemically modified nucleotide.
- In vitro potency gate: 10 nM dsRNA to HepG2 cells yields ≥80% inhibition of TTR mRNA measured by real-time PCR.
Claim 2:
- Same dsRNA definition as claim 1.
- In vivo exposure potency gate: human ED50 < 0.03 mg/kg.
Claim 3:
- Same dsRNA definition as claim 1 (sequence motif and complement; at least one chemically modified nucleotide).
- In vivo pharmacodynamic gate: reduces human serum TTR protein ≥50% vs baseline at dose <0.03 mg/kg.
Claim 4:
- Same dsRNA definition as claim 1.
- In vivo pharmacodynamic gate + dose specific: reduces human serum TTR ≥70% at 0.3 mg/kg.
Claim strategy: The patent attempts to lock protection to (a) a specific target-site dsRNA motif and complementarity rules, and (b) assayable performance thresholds that can be used to distinguish later entrants.
Dependent claims that narrow to specific modifications and sequences
- Modified nucleotides (Claim 5): 2’-O-methyl and/or 5’-phosphorothioate group.
- Specific sense/antisense sequences:
- Claim 6: sense strand contains GUAACCAAGAGUAUUCCAUNN (SEQ ID NO:449) (complements the antisense motif).
- Claim 7: antisense contains AUGGAAUACUCUUGGUUACdTdT (SEQ ID NO:730).
- Claim 8: sense contains GUAACCAAGAGUAUUCCAUdTdT (SEQ ID NO:729).
- Claims 9: sense complement to Claim 7 antisense (SEQ ID NO:729).
- Fully specified nucleotide identity with 2’-O-methyl + terminal dTdT analogs:
- Claim 10: antisense consists of AUGGAAuACUCUUGGUuACdTdT (SEQ ID NO:1010) with u = 2’-O-methyluridine and dT = 2’-deoxythymidine.
- Claim 11: sense consists of GuAAccAAGAGuAuuccAudTdT (SEQ ID NO:1009) with analogous definitions.
- Length-dependent variants (Claims 12–15): explicitly 21 nt sense in multiple dependent claims.
- Modification count constraints (Claims 16–17):
- antisense has 4 modified ribonucleotides (Claim 16).
- sense has 11 modified ribonucleotides (Claim 17).
- Assay/dose refinement (Claims 18 and 33–34):
- HepG2 10 nM yields ≥90% inhibition.
- Cell type and concentration fixed.
Delivery system scope (Claims 19–22; 39–46; 43–46)
- Claim 19: formulated in a lipid formulation.
- Claim 20: formulated in a LNP formulation.
- Claim 21: LNP11 composition: MC3/DSPC/Chol/PEG2000-C14 = 50/10/38.5/1.5 mol%.
- Claim 22: same lipids plus lipid:siRNA ratio ~11:1.
The repeated claim “echo” (composition claims 31–42 and formulation claims 39–46) indicates the same delivery system is positioned as part of the protected composition when paired with the defined dsRNA sequences.
How do the potency thresholds in US 10,240,152 define enforceable dsRNA scope?
This patent uses functional claim elements that can materially affect infringement analysis. The thresholds become part of claim scope, creating both leverage and potential defenses for an accused product that differs in potency at comparable dosing.
In vitro restriction
- HepG2 real-time PCR assay:
- Claim 1: ≥80% inhibition at 10 nM.
- Claim 18 / Claim 33: ≥90% inhibition at 10 nM.
- Claim structure ties the potency to TTR mRNA expression; an accused product that reduces mRNA but below the threshold could be outside the claim range.
In vivo restriction
- ED50-based claim (Claim 2): human ED50 < 0.03 mg/kg.
- Serum TTR protein reduction claims (Claims 3–4):
- ≥50% at dose <0.03 mg/kg (Claim 3).
- ≥70% at 0.3 mg/kg (Claim 4).
Practical implication: A competitor can design around the sequence motif while still hitting pharmacodynamic effects, or vice versa, but the claims require both structural (dsRNA motif/length/modification) and performance thresholds to align.
Which dsRNA sequences are specifically claimed in US Patent 10,240,152?
Motif-level (broad claim anchor)
- Antisense includes: AUGGAAUACUCUUGGUUACNN (SEQ ID NO:450).
- Sense is defined by complementarity to the antisense region.
- Length flexibility: 19–24 nt on both strands.
This creates a zone of coverage around the core binding site while allowing variation in the NN positions and length edges, constrained by complement and assay potency.
Exact sequence-level claims (strongest target specificity)
The patent also drills down to exact strands with standardized nucleotide identity conventions:
- Antisense (SEQ ID NO:1010): AUGGAAuACUCUUGGUuACdTdT
- Sense (SEQ ID NO:1009): GuAAccAAGAGuAuuccAudTdT
These exact-sequence dependent claims reduce ambiguity and typically increase infringement risk for products using the identical strand architecture and modification chemistry.
What does the lipid/LNP formulation coverage include in US 10,240,152?
LNP lipid mixture and ratio (explicit)
- MC3/DSPC/Chol/PEG2000-C14 = 50/10/38.5/1.5 mol% (Claims 21, 43).
- Lipid:siRNA ratio ~11:1 (Claim 22 and same formulation set across related claims).
Delivery alternative breadth
- Claims only specify “lipid formulation” generally before narrowing to LNP and then to the precise formulation.
- If an accused product uses a different LNP lipid composition, it can fall outside dependent claims, but still may be evaluated under the broader “lipid formulation” scope if the earlier claims are not restricted by the exact LNP11 composition.
What method-of-use claims exist in US Patent 10,240,152 and what schedules/doses are protected?
In vitro method
- Claim 23: contacting a mammalian cell with the pharmaceutical composition and maintaining it for a time sufficient to obtain mRNA transcript degradation of TTR.
Treatment of transthyretin amyloidosis
- Claim 24: administering to a human subject with transthyretin amyloidosis.
- Claim 25: dosing interval limits (not more than 2, 3, or 4 week interval).
- Claim 26: every 3 to 4 weeks.
- Claim 27: dose 0.3 mg/kg.
- Claim 28: symptom set includes polyneuropathy, cardiomyopathy, gastrointestinal dysfunction, weight loss.
- Claim 29: serum TTR reduction thresholds:
- ≥70% or ≥80% vs prior treatment.
Hereditary transthyretin mediated amyloidosis (IV infusion specifics)
- Claim 30: intravenous infusion regimen:
- 0.3 mg dsRNA/kg every three weeks
- dsRNA composition is exactly SEQ ID NO:1009 + SEQ ID NO:1010
- LNP formulation is MC3/DSPC/chol/PEG-DMG at ~50/10/38.5/1.5 mol% (language parallels the LNP11 set).
The method claim set couples schedule and exact chemistry, providing strong leverage against copycat dosing regimens for the specific dsRNA and LNP.
When does US 10,240,152 lose exclusivity?
No answer is possible from the claim text alone. Exclusivity timing depends on:
- application and priority dates,
- patent grant date,
- statutory term (20 years from earliest effective non-provisional filing, subject to adjustments),
- patent term adjustment (PTA) and any terminal disclaimer,
- potential regulatory exclusivity interactions (for dsRNA drugs, typically 5-year NCE or 3-year new clinical investigation, but only if applicable), and
- whether the patent has been enforced, settled, or limited in reexamination or litigation.
Without the bibliographic record (filing/priority, PTA, and maintenance status), a precise exclusivity calendar cannot be produced.
How strong is the patent estate for this TTR dsRNA approach in the US based on claim structure alone?
Strength indicators embedded in claim drafting
- Specific target motif (SEQ ID NO:450 core) reduces “any dsRNA against TTR” breadth.
- Exact sequence dependent claims (SEQ ID NO:1009/1010) increase enforceability against products using that exact duplex design.
- Quantitative potency gates (HepG2 mRNA inhibition and human serum TTR reduction) make straightforward “similar mechanism” arguments less effective.
- Delivery formulation constraints (LNP lipid set and lipid:siRNA ratio) can narrow design-arounds, especially where competitors use the same or near-identical LNP.
Strength limits exposed by functional gates
- Functional thresholds can create difficult infringement proof burdens for the patentee when comparing to the accused product’s performance under comparable conditions.
- Competitors can potentially change:
- dosage form delivery composition,
- length/modification pattern,
- potency achieved at the defined doses,
- or use a different binding site that avoids the motif.
What generic entry risks exist for a TTR dsRNA competitor under these claims?
High-risk scenario
A competitor that:
- uses the same (or highly similar) antisense core containing AUGGAAUACUCUUGGUUACNN,
- maintains the sense complementarity rules,
- uses chemically modified nucleotides consistent with the dependent claims (2’-O-methyl and/or phosphorothioate),
- and matches at least one key potency threshold (≥80% at HepG2 10 nM or ≥50% serum TTR at <0.03 mg/kg, etc.),
- and uses an LNP with the same lipid composition and ratios,
faces substantial infringement risk.
Lower-risk design-around paths
- Change the antisense core so the antisense does not include the exact motif with allowable variations (impacts both broad and dependent sequence definitions).
- Use a different modification pattern or change the effective strand architecture so performance falls short of the claimed thresholds at the defined dosing.
- Switch to an LNP composition materially different from MC3/DSPC/Chol/PEG2000-C14 ~50/10/38.5/1.5 mol% and avoid the lipid:siRNA ratio restriction (for dependent claims).
How do these claims compare with typical siRNA/TTR IP patterns (motif + LNP + potency gates)?
This claim set aligns with the emerging siRNA/dsRNA portfolio structure in TTR RNA interference:
- duplex sequence definition by a target-site motif,
- explicit chemical stabilization elements (2’-O-methyl, phosphorothioate, and terminal dTdT),
- and LNP specificity.
The novelty is the pairing of:
- a fixed antisense target motif with length flexibility, and
- explicit quantitative performance thresholds tied to assay modality (HepG2 qPCR) and clinical pharmacodynamics (human serum TTR reduction at specific doses/ED50).
What litigation, Orange Book status, or FDA pathway implications apply to US 10,240,152?
No answer is possible from the provided content. Orange Book listing is only relevant if the drug is coded with an eligible submission; biologics are typically not in the Orange Book. FDA pathway details (NDA vs BLA, reference product, exclusivity start/end) and any Orange Book patent linkage for this specific US patent require the drug’s identity and FDA submissions.
Key Takeaways
- US 10,240,152 protects dsRNA duplex compositions that inhibit TTR using a defined antisense motif (AUGGAAUACUCUUGGUUACNN, SEQ ID NO:450) and complementary sense architecture.
- Scope is constrained by strand length (19–24 nt), chemical modification presence, and quantitative potency thresholds in HepG2 qPCR and human serum TTR protein reduction or ED50.
- Strongest infringement exposure is tied to exact duplex sequences: antisense SEQ ID NO:1010 and sense SEQ ID NO:1009, plus defined LNP lipid ratios (MC3/DSPC/Chol/PEG2000-C14 ~50/10/38.5/1.5 mol%).
- Method claims protect IV dosing schedules and 0.3 mg/kg every three weeks (for the exact sequence + LNP combination), with defined therapeutic endpoints based on TTR reduction.
- A complete exclusivity calendar, litigation posture, and FDA/Orange Book linkage cannot be derived from the claims text provided.
FAQs
-
Do these claims cover any dsRNA that reduces TTR mRNA, or only those containing SEQ ID NO:450?
The claims anchor coverage to a dsRNA containing the SEQ ID NO:450 motif in the antisense and complementary sense pairing, plus modification and potency requirements.
-
What is the highest-risk design target for a competitor: sequence or formulation?
Both. Exact-sequence dependent claims (SEQ ID NO:1010/1009) and explicit LNP composition/ranges (MC3/DSPC/Chol/PEG2000-C14 ~50/10/38.5/1.5 mol%) create layered infringement risk.
-
Can an engineered product avoid infringement by reducing serum TTR less than the claimed thresholds?
That is a direct design lever because serum TTR reduction and ED50 thresholds are part of claim scope for key independent claims.
-
Are the HepG2 qPCR thresholds sufficient alone to establish infringement?
Not for independent claims that also require the structural dsRNA definition (motif/complement/length/modification) and, for certain claims, human ED50 or serum protein reduction.
-
Does changing the LNP lipid composition automatically avoid all claims?
It may avoid dependent claims that specify the LNP11 lipid composition and lipid:siRNA ratio, but it does not eliminate risk under claims that only require “lipid formulation” unless the broader claims are construed to be limited by those dependent formulation elements.
References
- Claims provided in prompt for US Patent 10,240,152 (no external bibliographic sources cited).
More… ↓
⤷ Start Trial
|
